Omda（OMDA）株式概要
Omda ASは、ノルウェー、スウェーデン、デンマーク、フィンランド、そして世界各国で、ヘルスケア分野のソフトウェア・ソリューションを提供しています。 詳細
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omda AS 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | NOK 36.10 |
| 52週高値 | NOK 56.60 |
| 52週安値 | NOK 33.00 |
| ベータ | 0.42 |
| 1ヶ月の変化 | -6.23% |
| 3ヶ月変化 | -6.48% |
| 1年変化 | -28.09% |
| 3年間の変化 | -25.10% |
| 5年間の変化 | -60.11% |
| IPOからの変化 | -56.51% |
最新ニュース
ナラティブの更新 • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.分析記事 • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...ナラティブの更新 • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Recent updates
ナラティブの更新 • Jun 02
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Shape Future Upside Potential
Narrative Update on Omda The updated analyst price target for Omda shifts from a fair value of NOK57.00 to NOK50.00 as analysts factor in a higher discount rate, more cautious revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple. Analyst Commentary Recent Street research on Omda highlights a mix of optimism about growth and execution, paired with more cautious valuation assumptions and price target resets.分析記事 • May 23
Omda AS (OB:OMDA) Just Reported, And Analysts Assigned A kr50.00 Price Target
Last week, you might have seen that Omda AS ( OB:OMDA ) released its quarterly result to the market. The early response...ナラティブの更新 • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.ナラティブの更新 • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.ナラティブの更新 • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.ナラティブの更新 • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.ナラティブの更新 • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.ナラティブの更新 • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.ナラティブの更新 • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.ナラティブの更新 • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.ナラティブの更新 • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.ナラティブの更新 • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.ナラティブの更新 • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.ナラティブの更新 • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.分析記事 • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...ナラティブの更新 • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.分析記事 • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...分析記事 • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...新しいナラティブ • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.分析記事 • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...分析記事 • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...分析記事 • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...分析記事 • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...分析記事 • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...分析記事 • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...分析記事 • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...分析記事 • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...分析記事 • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...株主還元
| OMDA | NO Healthcare Services | NO 市場 | |
|---|---|---|---|
| 7D | -0.6% | -2.3% | -0.5% |
| 1Y | -28.1% | -15.8% | 12.7% |
業界別リターン: OMDA過去 1 年間で-15.8 % の収益を上げたNorwegian Healthcare Services業界を下回りました。
リターン対市場: OMDAは、過去 1 年間で12.7 % のリターンを上げたNorwegian市場を下回りました。
価格変動
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 5.8% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in NO Market | 10.8% |
| 10% least volatile stocks in NO Market | 3.1% |
安定した株価: OMDA 、 Norwegian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: OMDAの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1999 | 256 | Sverre Flatby | omda.com |
オムダASは、ノルウェー、スウェーデン、デンマーク、フィンランド、および海外において、ヘルスケア分野向けのソフトウェア・ソリューションを提供している。血液・細胞・組織管理システムOmda ProSangからなる検査情報管理システムや、腫瘍治療管理ソリューションOmda Cytodoseからなる医療投薬ソリューションを提供している。また、コネクテッド・ヘルスケア・ソリューションとして、心電図・診断保存ツール「Omda Cardio」、医用画像モバイルアプリ「Omda CIMA」、ウェブベースの医用画像ソリューション「Omda Media」、画像管理・ワークフロー「Omda Medimaker」、画像管理ソリューション「Omda Picsara」、統合遠隔画像診断システム「Omda Arcidis」、患者データ転送ツール「Omda Helsemail」、監査・ワークフロー監視プラットフォーム「Omda Plutus」、セキュアなeケアコミュニケーションプラットフォーム「Omda S7」、患者データ保存・管理ソリューション「Omda XDS」を提供している。また、高度生殖補助医療クリニック向けデータソリューション「Omda Fertsoft」、デジタルマタニティソリューション「Omda iPana Hospital」、女性マタニティケア向けクラウドベースプラットフォーム「Omda iPana Maternity」、マタニティセクター向けデータソリューション「Omda Partus」、医療データ管理ソリューション「Omda Compos」、医療データの収集・分析・管理ソリューション「Omda MedSciNet」などの健康分析製品も提供している。さらに、救急組織がデジタルシミュレーションを通じてリソースの配分や運用戦略をテストできる「Omda Optima」、統合救急対応プラットフォーム「Omda CoordCom」、救急通報を処理し、医療対応のさまざまな側面を調整するためのデジタルプラットフォーム「Omda AMIS」、救急対応システム「Omda Paratus」を提供している。同社は以前CSAM Health Group ASとして知られていたが、2023年9月にOmda ASに社名を変更した。オムダASは1999年に設立され、ノルウェーのオスロに本社を置いている。
Omda AS 基礎のまとめ
| OMDA 基礎統計学 | |
|---|---|
| 時価総額 | NOK 742.38m |
| 収益（TTM） | -NOK 35.92m |
| 売上高(TTM) | NOK 493.60m |
1.5x
P/Sレシオ-20.6x
PER（株価収益率OMDA は割高か？
公正価値と評価分析を参照収益と収入
| OMDA 損益計算書（TTM） | |
|---|---|
| 収益 | NOK 493.60m |
| 売上原価 | NOK 258.75m |
| 売上総利益 | NOK 234.85m |
| その他の費用 | NOK 270.77m |
| 収益 | -NOK 35.92m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 27, 2026
| 一株当たり利益（EPS） | -1.75 |
| グロス・マージン | 47.58% |
| 純利益率 | -7.28% |
| 有利子負債／自己資本比率 | -2,394.2% |
OMDA の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
1.3%
現在の配当利回り-27%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/19 18:59 |
| 終値 | 2026/06/19 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Omda AS 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |